Forget Moderna -- This Is A More Lucrative Coronavirus Stock
Moderna (NASDAQ: MRNA) is without a doubt one of the most talked about coronavirus stocks these days. The company was the first to launch its coronavirus vaccine candidate in human trials and is still a leader in the race to the finish line. As of Oct. 27, shares of the clinical stage biotech company had climbed 257% so far this year, rewarding those who got in on its growth story early.
But for the long-term investor, there may be more lucrative bets than Moderna. I'm thinking of one of my favorite coronavirus stocks, Abbott Laboratories (NYSE: ABT). Sure, Abbott is only up around 25% this year. And I don't expect the stock to post triple-digit gains in a matter of months like Moderna did. But investors who buy Abbott shares now are likely to see solid returns over time.
Let's have a look at why we should be optimistic about this company.
Source Fool.com
